IPO Traffic: Week Ending Jan. 3, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Argos Therapeutics  (ARGS) Piper Jaffray/ Stifel/ JMP Securities       $60.00 n.a.
Dicerna Pharmaceuticals (DRNA) Jefferies/ Leerink Swann/ Stifel       $69.00 n.a.
Eleven Biotherapeutics (EBIO) Citigroup/ Cowen and Company/ Leerink Swann     $69.00 n.a.
Fortress Transportation and Infrastructure Investors Ltd.  (TBA) Barclays/ Deutsche Bank Securities       $100.00 n.a.
IMS Health Holdings  (IMS) J.P. Morgan/ Goldman Sachs/ Morgan Stanley     $100.00 n.a.
Revance Therapeutics (RVNC) Cowen and Company/ Piper Jaffray       $86.25 n.a.
uniQure B.V.   (QURE) Jefferies/ Leerink Swann       $75.00 n.a.
n.a. (not available)            
New Terms            
Acucela (TBA) Mitsubishi UFJ/ Morgan Stanley Securities Co., Ltd. 9.20 $15.00 $18.00 $151.80 (*)
(*) These shares will be offered in Japan and to investors located in jurisdictions other than the United States. Its  
common stock is expected to be listed on the Mothers market of the Tokyo Stock Exchange.      
IPOs Priced Lead Shares Amount Offer Close %
Week of Dec.  30, 2013 Manager(s) Offered Raised Price 1/3/14 Change